<DOC>
	<DOCNO>NCT01885559</DOCNO>
	<brief_summary>The efficacy interruption renin-angiotensin-aldosterone system ( RAAS ) progression cystic disease decline renal function autosomal dominant kidney disease ( ADPKD ) assess two simultaneous multicenter randomize clinical trial target different level kidney function : 1 ) early disease define GFR &gt; 60 mL/min/1.73 m2 ( Study A ) ; 2 ) moderately advanced disease define GFR 25-60 mL/min/1.73 m2 ( Study B ) . Participants recruit enrol , either Study A B , first three year . Participants enrol Study B follow five-to-eight year , average length follow-up six half year . Combination therapy use angiotensin-converting-enzyme inhibitor ( ACE-I ) angiotensin-receptor blocker ( ARB ) . Monotherapy use ACE-I alone .</brief_summary>
	<brief_title>HALT Progression Polycystic Kidney Disease ( HALT PKD ) Study B</brief_title>
	<detailed_description>* Specific Aim Study B To study effect ACE-I/ARB combination therapy compare ACE-I monotherapy set standard blood pressure control ( 110-130/80 mm Hg ) time 50 % reduction baseline estimate Glomerular Filtration Rate ( eGFR ) , end-state renal disease ( ESRD ) death , hypertensive individual moderate renal insufficiency ( GFR 25-60 mL/min/1.73m2 ) . * Hypothesis test Study B In hypertensive ADPKD individual moderate renal insufficiency ( GFR 25-60 mL/min/1.73 m2 ) , intensive blockade RAAS use combination ACE-I/ARB therapy slow decline kidney function ACE-I monotherapy , independent standard blood pressure control ( 110-130/80 mm Hg ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Diagnosis ADPKD . Age 1549 ( Study A ) ; Age 1864 ( Study B ) . GFR &gt; 60 mL/min/1.73 m2 ( Study A ) ; GFR 2560 mL/min/1.73 m2 ( Study B ) . BP ≥130/80 receive treatment hypertension . Informed Consent . Pregnant/intention become pregnant 46 yr . Documented renal vascular disease . Spot urine albumintocreatinine ratio &gt; 0.5 ( Study A ) ≥1.0 ( Study B ) and/or finding suggestive kidney disease ADPKD . Diabetes require insulin oral hypoglycemic agent / fast serum glucose &gt; 126 mg/dl / random nonfasting glucose &gt; 200 mg/dl . Serum potassium &gt; 5.5 milliequivalent ( mEq ) /L participant currently ACEI ARB ; &gt; 5.0 mEq/L participant currently ACEI ARB . History angioneurotic edema absolute contraindication ACEI ARB . Intolerable cough associate ACEI define cough developing within six month initiation ACEI absence cause resolve upon discontinuation ACEI . Indication ( hypertension ) βblocker calcium channel blocker therapy ( e.g . angina , past myocardial infarction , arrhythmia ) , unless approve site principal investigator . ( PI may choose accept individual small dose one agent would otherwise eligible . ) Systemic illness necessitate nonsteroidal antiinflammatory drug ( NSAIDs ) , immunosuppressant immunomodulatory medication . Systemic illness renal involvement . Hospitalized acute illness past 2 month . Life expectancy &lt; 2 year . History noncompliance . Unclipped cerebral aneurysm &gt; 7mm diameter . Creatine supplement within 3 month screen visit . Congenital absence kidney ( also total nephrectomy Study B ) . Known allergy sorbitol sodium polystyrene sulfonate . Exclusions specific magnetic resonance ( MR ) imaging ( Study A ) .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>polycystic kidney disease</keyword>
	<keyword>polycystic</keyword>
	<keyword>kidney</keyword>
	<keyword>disease</keyword>
	<keyword>adpkd</keyword>
	<keyword>halt</keyword>
	<keyword>pkd</keyword>
	<keyword>blood pressure</keyword>
	<keyword>bp</keyword>
	<keyword>hypertension</keyword>
	<keyword>renal</keyword>
	<keyword>renin-angiotensin-aldosterone-system</keyword>
	<keyword>RAAS</keyword>
</DOC>